Mersana Therapeutics

Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. The company's primary product candidate, XMT-1522, is a HER2-targeted ADC in a Phase 1 dose escalation study primarily in breast cancer patients as well as non-small cell lung cancer (NSCLC) and gastric cancer. The company's second product candidate, XMT-1536, is an ADC targeting NaPi2b, an antigen expressed in ovarian cancer and NSCLC.
  • TickerMRSN
  • ISINUS59045L1061
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

David Nierengarten ...
  • Jeffrey La Rosa

ASCO a Go for 1536; This Is Not a Drill

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

ValuEngine Rating and Forecast Report for MRSN

GlobalData Department

Mersana Therapeutics Inc (MRSN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp is a clinical-stage biopharmaceutical company that offers antibody drug conjugate to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes Fleximer antibody drug conjugation (ADC) platform, Dolaflexin to design ADC’s with drug-to-antibody ratios. Mersana's Dolaflexin platform offers custom design of an ADC with specific properties to target a particular type of cancer. The company develops immunoconjugates to deliver payloads of anti t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch